twitter-stripe
blog-stripe

FCI Launches In House Egg Donor Program
Read about how we are now providing a one stop shop for couples

Free e-newsletter
Subscribe now to monthly news delivered directly to you

Events & Seminars
See a list of all our fertility support groups and classes 

Success Rates

How to go beyond the numbers English French German Italian Japanese Portuguese Russian Spanish

PGD Program

PDF Print E-mail
AddThis Social Bookmark Button

Preimplantation Genetic Diagnosis (PGD) is a state of the art procedure used in conjunction with in vitro Fertilization (IVF) to select embryos free of chromosomal abnormalities and specific genetic disorders for transfer to the Uterus. These genetic conditions can interfere with Embryo Implantation, result in pregnancy loss, or in the birth of a child with physical problems, developmental delay or mental retardation.

 

PGD may be recommended by your physician when there is a possibility, indicated by your medical history or advanced maternal age, that your embryos could be affected by a genetic disease. PGD testing can only be performed within the context of an IVF Cycle where eggs and sperm, united in the laboratory, develop into embryos. FCI offers PGD screening for chromosome disorders and single gene defects. Genetic testing on sperm from men with Male Factor Infertility or those carrying a balanced translocation is also performed. FCI as well conducts research to evaluate and continually improve the clinical application of PGD and to develop new tests and genetic therapies to benefit a wider variety of patients in the near future.

(continued below)

Watch an educational clip about PGD (also known as PGS) from our documentary –

Journeys: The Art and Science of Making a Baby

Order a free copy of the full DVD.

 

Indications for PGD

  • Recurrent Miscarriage

  • Unsuccessful IVF Cycles

  • Unexplained Infertility

  • Advanced Maternal Age

  • Male Factor Infertility

  • Inherited genetic disorders

Today, PGD technology reduces the potential for adverse pregnancy outcomes for couples ‘at risk’ by enabling us the ability to test the embryos for certain genetic abnormalities before they are chosen for transfer back to the woman. For example: 10 embryos resulted from an IVF cycle and through PGD testing, 6 were identified as genetically abnormal and four were normal. Armed with this knowledge, only the normal embryos would be selected for embryo transfer thereby reducing the possibility of miscarriage or birth defects.